Search Site
Contact Details

CALL: +44 (0)8446 696907

Contact Details
InflammaDry

AN IN-PRACTICE TEST TO AID IN DRY EYE DIAGNOSIS

InflammaDry® is the only rapid, in-practice dry eye test that detects MMP-9, a biomarker for inflammation that is consistently elevated in the tears of dry eye patients. All other dry eye tests measure tear production and stability. InflammaDry® recognises elevated levels of MMP-9 to identify patients that may otherwise be missed with other dry eye testing methods.

Identify Dry Eye

Dry eye disease, or dysfunctional tear syndrome, is an extremely common condition that is often under diagnosed and affects 5-30% of the population ages 50 and over.

InflammaDry® is the first and only, rapid, in-practice test that detects MMP-9, an inflammatory marker that is consistently elevated in the tears of patients with dry-eye disease.

Commit to making the right diagnosis with an easy-to-use, in-practice, dry eye test that gives accurate results in as little as 10 minutes.

Watch our Information Video

 

  • Detects elevated levels of MMP-9 in tear fluid, to identify inflammation.
  • Provides rapid results, as soon as 10 minutes.
  • Accurate, with higher sensitivity and specificity, than other dry eye tests.
 

CLINICAL BENEFITS OF IDENTIFYING DRY EYE

 
  • By identifying and treating patients with dry eye, pre-surgical measurements are more accurate and post-surgical outcomes are improved.
  • Reduce post-surgical complications, such as corneal wound healing, by identifying dry eye prior to surgery.
  • Therapeutic treatment of dry eye will improve patient quality of life
 

CONFIDENCE IN DRY EYE DIAGNOSIS

 
  • Disposable, in-practice diagnostic test that requires just 4 easy steps.
  • Low cost test requires no additional equipment to administer or interpret.

RIGHT DIAGNOSIS

  • MMP-9 is a more sensitive diagnostic marker for dry eye than clinical signs alone.
  • Inflammation is present before the clinical signs of dry eye.
  • Increased MMP-9 activity in dry eyes may contribute to deranged corneal epithelial barrier function, increased corneal desquamation, and corneal surface irregularity.

RIGHT TREATMENT

  • Dry eye disease may require an extensive treatment plan and continuous therapy.
  • Artificial tears and punctal occlusion may improve signs and symptoms, while helping to decrease visual irritation. 
  • Anti-inflammatory therapies have been shown to decrease MMP-9 activity.

RIGHT NOW

  • Results as soon as 10 minutes.

Latest Events

NEG & Independents Day 2018

Event Date: 28th October 2018 - 29th October 2018

Event Region:

GLASKLAR and Positive Impact will once again be returning to the NEG and Independents Day 2018 
 

"Last year we saw a significant merger in the events side of our industry when the team behind Independents Day agreed to join forces with National Eyecare Group to run our conferences on the same weekend. The combined event was a huge success for all sides of the industry with a record 255 delegates registered and one fewer exhibition for suppliers to financially support. 

In order to thrive, independent practitioners also need to operate sound business and clinical practice in equal measure. Recognising this difficult combination of skills our focus is biased towards business development and simply being the most commercially successful practice you can be.

If you work in an independent practice, whether optician or optometrist, practice owner or practice team member - you are ALL welcome to attend. 

This year we look forward to meeting friends old and new, whilst celebrating all that's good about being independent!"

Read more